Levine, Arnold J. http://orcid.org/0000-0002-1871-6387
Article History
Received: 9 March 2022
Revised: 14 March 2022
Accepted: 14 March 2022
First Online: 5 April 2022
Competing interests
: AJL is a founder, shareholder, receives fees from, and is a member of the board of directors of PMV pharmaceutical company, which produces small molecules that reactivate mutant p53 proteins. He also chairs the SAB of Janssen Pharmaceutical company and is a member of the board of Meira GTX, a gene therapy company for restoring eyesight. He is also a member of the board of directors of GeneCentric, a RNA seq diagnostic company for cancer treatments. He also receives funding from a grant from the NCI, P01CA087497-20, and is a member of the SAB of Rome, a company that explores the role of repetitive DNA sequences in cancers.
: This editorial did not require ethics approval.
Free to read: This content has been made available to all.